Multiple Myeloma

Addition of Darzalex™ Improves Outcomes in Newly Diagnosed Multiple Myeloma (12-13-2017)

The addition of Darzalex (daratumumab) to the standard treatment combination consisting of Velcade (bortezomib), melphalan, and prednisone (VMP) reduces disease progression or death by 50%, among patients with newly diagnosed multiple myeloma who are... Continue Reading

Diagnosed with Multiple Myeloma: 10 Tips on How to Get The Most From Your Doctor (11-20-2017)

1) Choose Your Doctor Carefully Hematologists and oncologists are the primary doctors involved with multiple myeloma and often work in collaboration with stem cell transplant physicians. Pick your primary hematologist/oncologist carefully, rely on people... Continue Reading

FDA Adds Two Roche Multiple Myeloma Studies Evaluating Checkpoint Inhibitors to List of Partial Clinical Holds Over Safety Concerns (09-25-2017)

Alarmed that an imbalance in deaths among patients taking a combination of Keytruda (pembrolizumab) with Celgene’s Pomalyst and Revlimid could represent a threat in that whole class of checkpoint comboinations, the FDA has added two Tecentriq (atezolizumab)... Continue Reading

Four-Year Follow-up with Empliciti Plus Revlimid in Patients with Advanced Multiple Myeloma Shows Long-term Beneift (07-13-2017)

Four-year follow-up data from the Phase 3 ELOQUENT-2 clinical trial in which Empliciti (elotuzumab) plus Revlimid (lenalidomide) continued to demonstrate effectiveness in patients with relapsed/refractory multiple myeloma compared to patients treated... Continue Reading

Revlimid Maintenance Therapy Related to More Secondary Primary Malignancies in Older Adults (04-25-2017)

Results from a pivotal clinical trial have supported the use of Revlimid (lenalidomide) as maintenance therapy for patients multiple myeloma.  A new analysis from the trial just published in the Journal, Blood raises concerns about the safety of Revlimd... Continue Reading

FDA Expands Indication for Revlimid® as a Maintenance Treatment for Patients with Multiple Myeloma Following Autologous Stem Cell Transplant (03-28-2017)

The U.S. Food and Drug Administration (FDA) expanded the existing indication for Revlimid® (lenalidomide) to include use for patients with multiple myeloma as maintenance therapy following autologous stem cell transplant (ASCT). The expanded indication... Continue Reading

Kyprolis® Significantly Improves Overall Survival Compared To Velcade® In Relapsed Or Refractory Multiple Myeloma (03-22-2017)

The ENDEAVOR trial results were updated at the 16th International Myeloma Workshop in New Delhi.  The trial demonstrated that Kyprolis (Carfilzomib) not only significantly extended progression-free survival compared to Velcade (Bortezomib), but also... Continue Reading

Early Treatment in Smoldering Myeloma Improves Long-Term Outcomes (02-3-2017)

Use of the treatment combination consisting of Revlimid (lenalidomide) plus dexamethasone during smoldering myeloma appears to significantly improve long-term outcomes for patients. These results were published in The Lancet Oncology, and presented at... Continue Reading

Velcade® Revlimid®/Dexamethasone New Standard of Care for Newly Diagnosed Multiple Myeloma (01-31-2017)

The addition of the proteasome inhibitor Velcade® (bortezomib) to the treatment combination Revlimid® (lenalidomide) plus dexamethasone improves survival when used as initial therapy in multiple myeloma among patients who do not intend to immediately... Continue Reading

Scientific Highlights from American Society of Hematology Meeting (01-24-2017)

About CAR-T CAR-T, or chimeric antigen receptor T-cells, is a new form of cancer immunotherapy in which a patient’s own T cells are removed and then engineered to identify and kill malignant multiple myeloma cells. The use of a patient’s own immune... Continue Reading

Next Page »